Research programme: immune modulation therapy - Celldex Therapeutics Inc
Alternative Names: LOR-A04; LOR-S01; LOR-S03; αCD27xαPD-L1 bispecific antibodiesLatest Information Update: 28 May 2022
At a glance
- Originator Lorantis
- Developer Celldex Therapeutics Inc; Lorantis
- Class Antineoplastics; Bispecific antibodies; DNA; Immunotherapies; Proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic asthma; Cancer; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Viral infections